Save Comparison | ![]() Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. | ![]() Aimmune Therapeutics Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. | ![]() MyoKardia MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. | ![]() Otonomy Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. | ![]() Vertex Pharmaceuticals Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases. |
Founding Date | Founding Date 2002 | Founding Date 2011 | Founding Date 2012 | Founding Date 2008 | Founding Date 1989 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations Brisbane, US HQ München, DE Dublin, IE London, GB Durham, US | Locations South San Francisco, US HQ Brisbane, US | Locations San Diego, US HQ | |
Employees | Employees 22079% increase | Employees 2755% increase | Employees 23542% increase | Employees 49 | Employees 3,00020% increase |
Valuation ($) | Valuation ($) 3.9 b | Valuation ($) 2.3 b | Valuation ($) 12 b | Valuation ($) 193.4 m | Valuation ($) 58.6 b |
Twitter followers | Twitter followers 1.1 k | Twitter followers 1.6 k | Twitter followers 1.2 k | Twitter followers 214 | Twitter followers 65.2 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 14 | Number of tweets (last 30 days) 1 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 5 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 4.6 | Average likes per tweet (last 30 days) 8 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 30.2 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% |
Alexa Website Rank | Alexa Website Rank 283162 | Alexa Website Rank 193253 | Alexa Website Rank 239431 | Alexa Website Rank 339305 | Alexa Website Rank 145684 |
Employee Rating | Employee Rating 3.9 | Employee Rating 4.3 | Employee Rating 4.2 | Employee Rating 4.3 | Employee Rating 3.4 |
Financial | |||||
Revenue (est.) | Revenue (est.) $26.5m (FY, 2019) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $600k (FY, 2019) | Revenue (est.) $4.2b (FY, 2019) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $912k (FY, 2019) | Cost of goods $547.8m (FY, 2019) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit ($312k) (FY, 2019) | Gross profit $3.6b (FY, 2019) |
Net income | Net income ($290.2m) (FY, 2019) | Net income ($248.5m) (FY, 2019) | Net income ($276.2m) (FY, 2019) | Net income ($44.7m) (FY, 2019) | Net income $1.2b (FY, 2019) |
Operating ⚠ | |||||
Patents Issued | Patents Issued 240 (FY, 2016) | Patents Issued 2 (FY, 2016) | Patents Issued N/A | Patents Issued 88 (FY, 2016) | Patents Issued N/A |
Patents Pending | Patents Pending 280 (FY, 2016) | Patents Pending N/A | Patents Pending N/A | Patents Pending 115 (FY, 2016) | Patents Pending N/A |
Phase I Trials Products | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2018) | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products 2 (FY, 2018) | Phase II Trials Products 2 (FY, 2016) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2018) | Phase III Trials Products 2 (FY, 2016) | Phase III Trials Products N/A |
Pre-Clinical Phase Products | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products 3 (FY, 2018) | Pre-Clinical Phase Products 1 (FY, 2016) | Pre-Clinical Phase Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 468.9m | Total funding raised $ 145m | Total funding raised $ 98m | Total funding raised $ 153.4m | Total funding raised $ 2.4m |
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies.
View companyMyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
View companyOtonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
View companyVertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
View company